The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | EPCORE NHL-1: two and a half year follow-up of epcoritamab in DLBCL
Julie Vose, MD, University of Nebraska Medical Center, Omaha, NE, discusses the pivotal EPCORE NHL-1 trial (NCT03625037) of epcoritamab for diffuse large B-cell lymphoma (DLBCL), highlighting that patients have shown sustained complete remission (CR) with no long-term toxicity beyond two and a half years of treatment. The trial demonstrated promising results with high response rates in patients who had previously failed multiple therapies. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
